Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase 1b - to determine the recommended Phase 2 dose of LY2228820 that can be safely administered with gemcitabine and carboplatin Phase 2 - to compare the progression-free survival in patients treated with LY2228820 plus gemcitabine and carboplatin versus placebo plus gemcitabine and carboplatin
Critère d'inclusion
- Epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer